The gene-editing virtuoso CRISPR Therapeutics (NASDAQ: CRSP) is one of the most-watched stocks in biotech, and it's no surprise why. CRISPR Therapeutics has a handful of different programs that could turn out to be low-risk cures for previously intractable hereditary diseases. Smart investors are likely to disregard the notion that the company's revenue is actually growing.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting